Novotech, a leading biotech specialist CRO in the Asia-Pacific region, and virtual research organization (VRO) partner ObvioHealth have been selected as finalists for the Clinical Partnership of the Year Citeline Award by Informa Pharma Intelligence.
ObvioHealth is Novotech’s preferred provider for virtual clinical trials in APAC, while Novotech is ObvioHealth’s preferred CRO in the region for hybrid and virtual trials.
"Our efficient approach to conducting clinical trials is a key driver of our growth in the biotech space, where clients are seeking faster and more cost-efficient solutions," said John Moller, CEO at Novotech.
"Virtual trials offer patients greater access to the important clinical trials conducted across our region,” he added.
“Citeline’s recognition of this partnership with ObvioHealth further demonstrates to biotechs the exceptional access we offer for clinical research in the APAC region.”
Commenting on the partnership, Ivan Jarry, CEO of ObvioHealth said “Asia-Pacific is an area of opportunity for ObvioHealth– not only is it the fastest growing region for clinical trials, but we’re also seeing a growing interest in DCTs, especially from patients in APAC who are increasingly accepting and adopting digital health tools. Our partnership with Novotech provides us with the local expertise often required when conducting studies in APAC where regulatory agencies, language and cultural customs vary by country.”
Judges for the awards include some of the leading figures in biopharma.
According to Pharma Intelligence:
“Our commitment to awards entrants and attendees starts with the selection of independent judges who volunteer their time, experience, and consideration of the hundreds of entries to our various annual global awards. The judges, invited from all core sectors of the clinical R&D industry, engage in the judging process independently by using their industry knowledge and experience to score entries against the entry criteria. The judges' scores are all combined, giving us the shortlist and winners.”